Cytokinetics has revealed the results from a phase 3 trial of its hypertrophic cardiomyopathy (HCM) drug aficamten that it hopes will allow it to compete with Bristol-Myers Squibb’s first-to-market ...
On Wednesday, 11 March 2026, Cytokinetics Inc. (NASDAQ:CYTK) presented at the Barclays 28th Annual Global Healthcare Conference. The company highlighted its strategic focus on the global launch of ...
Performance in athletic activities that include a significant aerobic component at mild or moderate altitudes shows a large individual variation. Physiologically, a large portion of the negative ...
Cardiac myosin inhibitors were recently developed to address the underlying pathophysiology of hypertrophic cardiomyopathy and to improve symptoms and quality of life. In this review, we evaluated the ...
Denmark: Researchers have found in a new trial that among patients with nonobstructive hypertrophic cardiomyopathy (HCM), bisoprolol reduced peak oxygen consumption, whereas verapamil did not show ...
A 66-year-old man with dyspnea reported symptom onset 5 years ago, triggered by prolonged standing or walking, and relieved immediately with sitting. Dyspnea progressed over recent 6 months. He could ...
Abstract: Diazepam is an active ingredient of the drugs which is used in the treatment of the anxiety, insomnia, alcohol withdrawal, and muscle spasm. It has anxiolytic, sedative, muscle relaxant and ...
Correspondence to Professor Claire L Shovlin, Professor of Practice (Clinical and Molecular Medicine), NHLI Vascular Science, Imperial College London, Imperial Centre for Translational and ...
Customer stories Events & webinars Ebooks & reports Business insights GitHub Skills ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results